Podcasts about Roche

Audio roundup of selected biopharma industry content from Scrip over the business week ended Mar.13, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time – Roche faces giredestrant Phase III setback; founders exit BioNTech; Ipsen to withdraw Tazverik; tough times for Bayer; and another boost for UCB's Bimzelx. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-LMR3CRGKRFDWLHTOSBRDCRM7GE/ Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

What does it take to transform from a technical legal expert into a strategic conductor of organisational change? Keiko Uchida, Head of Legal and Compliance at Roche Diagnostics Japan, shares her journey to leadership from playing the figurative “violin in an orchestra” to becoming “the conductor.”Discover what it means to move from solving one case with 100 pieces of evidence to solving 100 questions with almost none, and why doubling productivity in Japanese companies has become Keiko Uchida's driving purpose.If you enjoyed this episode and it inspired you in some way, we'd love to hear about it and know your biggest takeaway. Head over to Apple Podcasts to leave a review and we'd love it if you would leave us a message here!In this episode you'll hear:The powerful conversation that shifted her entire career trajectoryWhy being a housewife became her greatest strength rather than a setbackHow Keiko is building a regional legal network across APAC Her favourite book and other fun facts About KeikoKeiko Uchida is the Head of Legal & Compliance at Roche Diagnostics K.K., where she sits on the leadership team as a direct report to the CEO and oversees legal affairs, compliance, data privacy, corporate governance, and risk management across the organisation.Since joining Roche in 2022, Keiko has played a pivotal regional leadership role, earning the “Change Maker of the Year 2024” award for APAC in recognition of her impact in building a high-performing, collaborative legal network across the region, as well as driving market-focused partnerships between legal, security, and commercial operations teams. One of her team members was also recognised as VIP of the Year 2024 within Roche Diagnostics Japan — a reflection of her strength as a people leader.Before Roche, Keiko served as Corporate Officer, General Counsel, Chief Compliance Officer, and Data Privacy Officer at AXA General Insurance Co., Ltd., where she led legal and compliance transformation initiatives during a period of organisational change. She previously held senior legal and corporate secretary roles within AXA, and earlier in her career practiced as a lawyer in private practice after completing her legal training in Japan.Keiko's career is uniquely cross-sector, with earlier professional experience in financial institutions including J.P. Morgan and Shinsei Trust Bank, as well as academic work as an Assistant Professor at a research center of The University of Tokyo. She later returned to the University of Tokyo to complete her J.D., following a Master's degree in law from Kyoto University.Recognised on the Legal 500 GC Powerlist Japan 2023, a panelist at GC Summit 2024, and co-author of a practical legal handbook on contract law published in 2023, Keiko is known for blending deep legal expertise with organisational leadership and strategic thinking.Her professional passion lies in balancing opportunity and risk while building high-performing organizations, and outside of work she enjoys traveling and exploring new cultures.Connect with KeikoLinkedIn: https://www.linkedin.com/in/keiko-uchida-3bab7a30/ LinksHow to Win Friends and Influence People: https://amzn.asia/d/09azrBtm Connect with Catherine LinkedIn https://www.linkedin.com/in/oconnellcatherine/Instagram: https://www.instagram.com/lawyeronair

Learn more about Maddy at: https://www.linkedin.com/in/maddy-roche-25962032/ https://childfreetrust.com/   Show Notes 

In this episode, Maddy Roche sits down with Zeena Regis, MDiv,  Director of Priority Populations at Compassion and Choices, to explore one of the most requested, and most avoided, conversations in the Childfree community: medical aid in dying.Zeena brings nearly 20 years of end-of-life experience, beginning as a hospice chaplain and evolving into a national advocate for equitable access to end-of-life options. She and Maddy unpack what medical aid in dying actually is, who it's for, and why having open conversations about death leads to better care for everyone, whether or not medical aid in dying is ever something you'd personally choose.In This Episode, You'll Learn:Why medical aid in dying is one option within a broader spectrum of end-of-life care, and what the legal safeguards around it actually look likeHow Childfree adults face unique risks when no healthcare proxy or estate documents are in place.How community, storytelling, and even art can open the door to death planning conversations that feel impossible to start aloneWhy having a healthcare proxy who truly knows you and is prepared to advocate for your wishes makes a difference in the quality of your final chapterJoin a Live Q&A with Zeena Regis: Title: Designing Your End-of-Life: A Live Q&A with Zeena Regis, MDivDate: 4/1/2026   Time: 5 PM EasternRegistration Link: https://us02web.zoom.us/webinar/register/WN_g-AYE_5GR1O2nRM-7l9tCg Episode Host:Maddy Roche: Chief Growth Officer at Childfree Trust® and responsible for all sales and marketing initiatives.Episode Guest:Zeena Regis, MDiv serves as the Director of Faith Engagement and Priority Populations at Compassion & Choices, improving care, expanding options, and empowering everyone to chart their end-of-life journey. Prior to her role with Compassion & Choices, Zeena served as a chaplain and grief care specialist for over a decade. Zeena also serves on the faculty of Columbia Theological Seminary's Older Adult Ministry Certification program and was selected as a 2024 American Society on Aging Fellow. Zeena is also a playwright, and her latest work, A Free Black Woman's Guide to Death & Dying, was selected for the Synchronicity Theatre's arts incubator project.Learn more about Compassion and Choices: https://compassionandchoices.org/ About Childfree InsightsChildfree Insights is a trusted resource for life planning without children. It explores financial planning, estate planning, relationships, and long-term decisions for adults building a future without kids. Home of Childfree Wealth® and Childfree Trust®.Connect with Us: Ready to work on building better financial habits? Connect with our financial planning team at childfreewealth.com or learn more about estate planning at childfreetrust.com. Follow Childfree Life by Design on your favorite podcast platform and join the conversation on social media: Instagram: https://www.instagram.com/childfreeinsightsFacebook: https://www.facebook.com/ChildfreeInsights/LinkedIn: https://www.linkedin.com/company/childfreeinsightsYouTube: https://www.youtube.com/@ChildfreeInsights Disclaimer: This podcast is for educational & entertainment purposes. Please consult your advisor before implementing any ideas heard on this podcast.

After Friday's news that Center for Biologics Evaluation & Research Chief Vinay Prasad will leave the FDA—again—at the end of April, stocks for several rare disease drug developers popped. UniQure, in particular, was up 51% in premarket trading on Monday. Prasad in a meeting last Thursday with select journalists called the biotech's Huntington's treatment AMT-130 a “failed” therapy, according to STAT News. Shares of Replimune and REGENXBIO—which have suffered rejections during the past year—also rose.One person who is not impressed with the plethora of rare disease drug rejections of late—H.C. Wainwright said in a note Tuesday that there have been at least five cell and gene therapies they believe could have been approved under prior FDA officials—is Wisconsin Senator Ron Johnson. Tuesday, Bloomberg News reported that Johnson has launched an investigation into these recent denials.Johnson called the FDA's request that uniQure conduct a sham surgery-controlled trial of AMT-130 “bureaucratic idiocy,” according to the publication. Meanwhile, uniQure and the FDA appear to be on different pages regarding the design of this prospective trial, with uniQure Chief Medical Officer Walid Abi-Saab referring to a 10-12 hour surgery during which [burr] holes would be drilled in patients' skulls and Prasad claiming on a media call last week that it would require only “one to three nicks in the scalp.”In other news, no episode of The Weekly would be complete without our weekly weight loss segment. Roche and Zealand Pharma's amylin analog fell short of Eli Lilly's rival candidate eloralintide; AbbVie reported what analysts called “competitive” results, with its amylin analog eliciting nearly 10% weight loss at 13 weeks in a Phase 1 trial; and Regeneron touted a much-needed Phase 3 win for Hansoh-partnered dual GLP-1/GIPR agonist olatorepatide in China. Beyond data, Novo Nordisk and Hims & Hers are together again, with Novo striking a deal to sell its injectable and oral GLP-1 medicines through the telehealth provider.Elsewhere on the business side of biopharma, experts are reporting a cut-throat atmosphere behind doors on the M&A front as the supply of companies available to buy dwindles.

Ecoutez les infos de ce lundi 09 mars à 12h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce lundi 09 mars à 08h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce lundi 09 mars à 07h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce lundi 09 mars à 06h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce lundi 09 mars à 09h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce dimanche 08 mars à 09h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce dimanche 08 mars à 12h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce dimanche 08 mars à 17h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce samedi 07 mars à 08h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce samedi 07 mars à 12h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce samedi 07 mars à 16h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce samedi 07 mars à 18h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

The Trump administration has reportedly ruled out deploying the Treasury Department to trade oil futures for now, believing it will have a limited meaningful effect, Bloomberg reported citing sources. US-sanctioned gas tanker reportedly transited the Strait of Hormuz this morning, according to Bloomberg; The Danuta I, sailed under the flag of Palau.European equities are under modest pressure, Roche hit as weight loss drug disappoints; US equity futures softer.DXY gains ahead of jobs report; AUD propped up by RBA hike bets; JPY narrowly lags peersGlobal bonds slip as the risk tone deteriorates; Gilts underperform.Crude continues to edge higher; Gold faces pressure amid a stronger DXY.Looking ahead, highlights include US NFP (Feb), Retail Sales (Jan), Speakers including ECB's Cipollone & Schnabel, Fed's Waller, Daly, Goolsbee, Miran, Schmid, Collins & Hammack, RBA's Hauser, Credit Review including Fitch on France, DBRS on Greece. Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

Avalancha de resultados un día más, con foco sobre Lufthansa, Roche, Advent y Eiffage como lo más destacado. Lo analizamos con Luis García Langa, analista en luisgarcialanga.com

Ecoutez les infos de ce vendredi 06 mars à 18h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce vendredi 06 mars à 16h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce vendredi 06 mars à 08h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce vendredi 06 mars à 19h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

In this episode, Maddy Roche sits down with Chris Dale, CFP®, CeFT®, founder of Life After Grief Financial Planning, to share the real-life story of helping a client navigate aging, medical emergencies, and end-of-life decisions.From hospice-informed insights to a sudden car accident just weeks after estate documents were signed, Chris walks through what actually happens when someone declines, and why having the right team and paperwork in place makes all the difference.This conversation is honest, practical, and grounded in lived experience. If you've ever wondered what planning for emergencies and end-of-life truly looks like without traditional next of kin, this episode will give you clarity.In This Episode, You'll Learn:Why Childfree individuals need both estate planning documents and a coordinated financial services team before a medical emergency occursHow powers of attorney and professional fiduciaries protect your healthcare decisions, financial accounts, and long-term care optionsWhat can go wrong when there is no clear next of kin, and how the state may become involved in decision-makingHow a financial advisor acting as a fiduciary helps manage insurance claims, hospital bills, and long-term care costs during crisisWhy building your aging plan early preserves autonomy, protects assets, and ensures your end-of-life wishes are honored.Episode Host:Maddy Roche - Chief Growth Officer at Childfree Trust® and responsible for all sales & marketing initiatives.Episode Guest:Chris Dale, CFP®, CeFT® is a financial advisor with 21 years of experience and the founder of Life After Grief Financial Planning™. As a CERTIFIED FINANCIAL PLANNER™ and Certified Financial Transitionist®, he specializes in guiding clients through the financial and emotional complexities of loss. His approach integrates technical planning with psychological insight rooted in his significant personal experience and 200+ hours of hospice volunteering.A five-time "Top Financial Advisor" in Orlando (2019–2023), Christopher is a prominent speaker, author, and host of the podcast Real Talk With Life After Grief Chris. Beyond his clinical expertise, he is a dedicated advocate for addressing how racism and discrimination intersect with grief. Through Life After Grief Consulting™, he provides CE-approved training, earning the reputation of the "Advisor's Advisor."He lives in Orlando with his wife and two sons.Learn more about Chris: Lifeaftergrieffp.com About Childfree InsightsChildfree Insights focuses on planning for solo aging and later life without children. It offers trusted education on financial planning, estate planning, and building support systems for people aging independently. Home of Childfree Wealth® and Childfree Trust®.Connect with Us: Ready to work on building better financial habits? Connect with our financial planning team at childfreewealth.com or learn more about estate planning at childfreetrust.com. Follow Childfree Life by Design on your favorite podcast platform and join the conversation on social media: Instagram: https://www.instagram.com/childfreeinsightsFacebook: https://www.facebook.com/ChildfreeInsights/LinkedIn: https://www.linkedin.com/company/childfreeinsightsYouTube: https://www.youtube.com/@ChildfreeInsights Disclaimer: This podcast is for educational & entertainment purposes. Please consult your advisor before implementing any ideas heard on this podcast.

The Public Service Commissioner is bewildered as pay talks with primary teachers drag on. Their union —the NZEI— has turned to the Employment Relations Authority after three days of talks failed to resolve disputes over cost-of-living increases and recognition for major curriculum changes. The union's rejected three offers, with teachers missing out on around $50 extra per week since January. Sir Brian Roche told Mike Hosking it's disappointing teachers don't know the details of each offer. He says the last time teachers were asked was in December, and he doesn't know what the percentage of the vote was. LISTEN ABOVE See omnystudio.com/listener for privacy information.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant advancements and ongoing challenges that are reshaping the landscape of these dynamic industries.A key highlight in recent developments comes from Ascendis Pharma, which has secured FDA approval for Yuviwel, a treatment targeting achondroplasia, a genetic disorder leading to dwarfism. This approval underscores the potential of Ascendis' "transient conjugation" drug delivery platform, marking its third rare disease drug approval in just six years. The platform's ability to extend drug half-life and improve dosing frequency highlights its promise in addressing unmet medical needs in rare diseases, offering new hope for patients who previously had limited treatment options.In oncology, Merck's LITESPARC clinical trial program is showing promising results with Welireg (belzutifan) for clear cell renal cell carcinoma. The trials suggest that combination therapies involving Welireg could set a new standard of care. However, transitioning these regimens into universal standards remains challenging due to competitive dynamics and hurdles in clinical adoption.Shifting to cardiovascular health, United Therapeutics has made notable progress with its phase 3 trial success for a once-daily drug candidate for pulmonary arterial hypertension. The trial reported a 55% reduction in clinical worsening risk, positioning United Therapeutics to seek FDA approval and potentially challenge existing treatments from major players like Johnson & Johnson.Regulatory challenges are also evident. UniQure recently faced a setback when the FDA rejected its data package for AMT-130, a gene therapy for Huntington's disease. This rejection reflects the stringent regulatory environment surrounding gene therapies and emphasizes the need for robust data to meet approval criteria.On the technological front, Eli Lilly is making a strategic shift by collaborating with Nvidia to integrate advanced computing capabilities into drug development. By leveraging Nvidia's AI-driven supercomputing power, Lilly aims to accelerate drug discovery processes and enhance precision medicine approaches, potentially transforming traditional pharmaceutical lifecycles.Operational shifts are also occurring as Merck winds down Gardasil production at its North Carolina plant due to declining global demand. This decision reflects broader vaccination trends and may signal shifts in manufacturing strategies to align more closely with market demands.Leadership changes at Bavarian Nordic, following a failed private equity takeover bid, indicate potential strategic realignments within the company. The planned departure of CEO Paul Chaplin after 12 years could herald new directions and priorities.In logistics, Frontier Scientific Solutions is pioneering advancements in temperature-controlled supply chains—crucial for maintaining drug efficacy during distribution. Their innovative approaches are reshaping pharmaceutical logistics, ensuring reliable delivery systems worldwide.Meanwhile, Walgreens is venturing into digital health with a virtual weight management clinic offering access to GLP-1 medications. This move positions Walgreens within the competitive telehealth market as it responds to growing consumer demand for convenient healthcare solutions.These developments collectively reflect an industry in flux—balancing scientific innovation with regulatory rigor and strategic realignments. As companies navigate these challenges, the implications for patient care are profound, promising potential improvements in treatment efficacy and accessibility.Turning our attention to Roche, another successful Phase 3 trial for fenebrutinib—a BTK inhibitor targeting relapsing multiple sclerosis—has been reported. The study achieved its primary endpoint but raiseSupport the show

In this episode, Maddy Roche and Bri Conn, CFP®, explain why legal documents alone aren't enough. Estate plans grant authority. Care plans provide direction. They spell out the details that make real-world care possible: where to find your mailbox key, your alarm code, how to feed your pets, what medical history your doctors should know, and what living with dignity truly means to you.They also discuss documenting cultural or religious preferences and why these plans should be treated as living documents, updated as your life, relationships, and values evolve.Key Takeaways:Estate plans give the who, care plans give the how. Legal documents grant someone the power to make decisions. Care plans outline what those decisions should actually look like, from daily routines to end-of-life wishes.Document the everyday details others wouldn't know. Alarm codes, mailbox locations, pet feeding routines, storage facilities, and where to find important items are all critical for someone stepping into your life.Define what life with dignity means to you. Cultural preferences, religious practices, LGBTQ+ identity, and personal boundaries should be clearly stated so your wishes are honored, not someone else's assumptions.Build a team to support you as you age. Financial planners, doctors, and aging care managers all play a role in ensuring your care plan can actually be executed when you need it.Treat your care plan as a living document. Update it as your life changes. New pet, new home, new diagnosis, new preferences. The goal is to keep it current so it reflects who you are now.Episode Hosts:Maddy Roche - Chief Growth Officer at Childfree Trust® and responsible for all sales & marketing initiatives.Bri Conn, CFP® - Customer Experience Manager at Childfree Trust®. Bri coaches clients through estate planning and care plan development, helping them document their wishes and build support teams.About Childfree InsightsChildfree Insights is a trusted resource for life planning without children. It explores financial planning, estate planning, relationships, and long-term decisions for adults building a future without kids. Home of Childfree Wealth® and Childfree Trust®.Connect with Us: Ready to work on building better financial habits? Connect with our financial planning team at childfreewealth.com or learn more about estate planning at childfreetrust.com. Follow Childfree Life by Design on your favorite podcast platform and join the conversation on social media: Instagram: https://www.instagram.com/childfreeinsightsFacebook: https://www.facebook.com/ChildfreeInsights/LinkedIn: https://www.linkedin.com/company/childfreeinsightsYouTube: https://www.youtube.com/@ChildfreeInsights Disclaimer: This podcast is for educational & entertainment purposes. Please consult your advisor before implementing any ideas heard on this podcast.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a compelling array of advancements and strategic shifts that are shaping the healthcare landscape across the globe.In recent times, the pharmaceutical and biotech sectors have showcased remarkable resilience and innovation, driving forward with significant scientific breakthroughs and clinical trial results. A standout achievement comes from Novo Nordisk, whose recent Phase 2 trial results for its triple agonist targeting obesity reported a remarkable weight loss of up to 19.7% in patients over 24 weeks. This promising development positions Novo Nordisk as a formidable contender in the obesity treatment market, potentially affecting giants like Eli Lilly. With obesity being a significant global health challenge, these findings underscore the potential of multi-targeted approaches in managing this complex condition.Regulatory landscapes continue to evolve, with pivotal approvals marking milestones for therapies targeting rare diseases. Immedica Pharma's Loargys received FDA approval for treating hyperargininemia associated with arginase 1 deficiency, highlighting perseverance in overcoming regulatory hurdles after a prior rejection. Additionally, Sanofi and Regeneron's Dupixent achieved its ninth FDA approval, underscoring its versatile potential across multiple indications. These approvals not only reflect regulatory progress but also emphasize the critical role of persistence in drug development.Ethical considerations remain at the forefront of industry discussions, particularly highlighted by Novartis' settlement in a lawsuit concerning the use of Henrietta Lacks' cells without consent. This resolution underscores ongoing ethical challenges within biomedical research, emphasizing the need for ethical vigilance as companies increasingly rely on human-derived materials.Significant business trends are shaping strategic directions within the industry. Pfizer's acquisition of marketing rights for Sciwind's GLP-1 receptor agonist in China exemplifies a calculated move to dominate the obesity treatment market. This strategic acquisition allows Pfizer to leverage China's vast market potential for type 2 diabetes medications and positions it favorably for future weight loss treatments.On the manufacturing front, AbbVie has made substantial investments in U.S. infrastructure, committing $380 million to new North Chicago API plants as part of a decade-long strategy to inject $100 billion into U.S. operations. This initiative highlights a commitment to bolstering domestic production capabilities amidst global supply chain uncertainties.The complexities of drug development are further illustrated by Roche's decision to halt the development of Enspryng for Duchenne muscular dystrophy due to unsatisfactory progress. This shift in focus reflects the inherent challenges of drug repurposing and the necessity of robust clinical evidence to support new indications.Geopolitical factors also play a significant role in shaping industry dynamics, with recent U.S. Supreme Court decisions impacting international trade agreements. Such geopolitical influences can significantly affect pharmaceutical companies' operations and strategic planning.The collaboration between Astellas and Vir Biotechnology reflects another significant trend in strategic partnerships within the industry. Their $1.7 billion deal centered on a novel bispecific T-cell engager for prostate cancer underscores the growing importance of immuno-oncology and innovative approaches to targeting hard-to-treat cancers.The regulatory front continues to see transformative changes with the FDA unveiling draft guidance for a new approval pathway tailored for bespoke gene-editing therapies. This initiative could expedite personalized genetic treatments and transform patSupport the show

Over 1.5million adults in the UK tried weight loss drugs in 2024-25. Many swear by them, but they have been associated with side effects including nausea and, in some cases, extremely painful gallstones. But what does the evidence actually tell us, and what is the wider impact on the way we view our bodies in society?James Gallagher is joined by Professor of Cardiometabolic Medicine at the University of Glasgow Naveed Sattar, Dr Beverley O'Hara, Lecturer in Public Health Nutrition at Leeds Beckett University, and Dr Margaret McCartney, resident Inside Health GP. They discuss what the evidence tells us about the potential known side effects of these weight loss drugs, and the potential impact their use has on our view of obesity as a society. We also hear from Sarah Le Brocq, who has struggled with obesity all her adult life and has been on these drugs for the past 2-3 years about her experiences. Margaret McCartney has no conflicts of interest to declare.Beverley O'Hara has no conflicts of interest to declare. She has 2 roles with the Association for the Study of Obesity (voluntary academic positions).Naveed Sattar has consulted for and/or received speaker honoraria from AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Carmot Therapeutics, Eli Lilly, Gan & Lee, GlaxoSmithKline, Hanmi Pharmaceuticals, Kailera, Mass Medicines, Menarini-Ricerche, Metsera, Novo Nordisk, Pfizer, Regeneron, Roche, UCB Pharma, and Verdiva Bio; and received grant support paid to his University from AstraZeneca, Boehringer Ingelheim, Novartis, and Roche.Presenter: James Gallagher Producer: Hannah Fisher Researcher: Tom Hunt Production coordinator: Stuart Laws Content Editor: Ilan Goodman

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the dynamic landscape of these industries, exploring significant regulatory shifts, scientific breakthroughs, and strategic corporate maneuvers that are shaping the future of healthcare.The pharmaceutical and biotech sectors are currently navigating a period of profound transition. Recent regulatory developments have captured attention, particularly the U.S. Supreme Court's decision to overturn emergency tariffs imposed by the previous administration. This ruling is pivotal as it alleviates financial pressures on the industry, allowing companies to redirect their resources towards innovation and development. It underscores the interconnectedness of global supply chains and highlights the importance of stable regulatory environments for fostering industry growth.In a notable advancement within oncology, AstraZeneca has achieved FDA approval for its combination therapy of Calquence and Venclexta as an all-oral regimen for first-line chronic lymphocytic leukemia (CLL). This approval not only positions AstraZeneca competitively in the BTK inhibitor market but also signifies a shift towards more patient-friendly treatment regimens. By simplifying therapy, this development promises to enhance patient compliance and improve outcomes, challenging existing standards in CLL care.Meanwhile, internal challenges at the Centers for Disease Control and Prevention have led to a postponement of a critical vaccine advisory panel meeting. This delay occurs amid evolving vaccine policies that have sparked debate within the public health community, potentially impacting immunization strategies and initiatives aimed at bolstering public health.Corporate governance within the industry is also experiencing shifts. Novo Nordisk has nominated two industry veterans to its board as part of an ongoing strategy to align leadership with evolving business objectives. Similarly, Roche is contemplating divesting its once-blockbuster antibiotic Rocephin in response to competitive pressures from generics in Europe. These moves reflect a broader industry trend where companies are re-evaluating their portfolios to better respond to market dynamics and patent expirations.Novartis is making strategic changes as well by selling its stake in Novartis India Limited while maintaining separate commercial and R&D interests in the region. This action highlights a growing trend among pharmaceutical giants towards streamlining operations and focusing on high-growth areas—a strategy aimed at maximizing resource allocation efficiency.Despite narrowly missing a $1 billion revenue target for 2025, Madrigal Pharmaceuticals remains optimistic about the growth prospects of its drug Rezdiifra within the metabolic dysfunction-associated steatohepatitis (MASH) market. The company anticipates further expansion driven by unmet medical needs, underscoring the competitive dynamics within this therapeutic area.In personnel movements that could influence strategic directions, Daiichi Sankyo has appointed former Novartis CMO John Tsai as head of its R&D division. His expertise is expected to bolster Daiichi's focus on oncology and other critical therapeutic areas, potentially accelerating innovation within their drug development pipeline.Meanwhile, Manus Bio has secured a $15 million contract with the U.S. government for domestic supply of shikimic acid, an essential component for producing Tamiflu. This contract highlights efforts to strengthen domestic pharmaceutical supply chains amid global uncertainties—a crucial consideration for ensuring medication availability during crises.In clinical research, a setback was observed with Grail's Galleri cancer blood test trial failing to meet its primary endpoint in collaboration with the NHS. The resulting decline in GrailSupport the show

Eli Hemming: From Olympic Triathlon to Trail Ultras, UTMB Goals, and the Joshua Tree TraverseRyan Maguire sits down with Eli Hemming, former elite professional triathlete turned trail runner, for a wide-ranging conversation about reinvention, endurance, and what drives an athlete when the Olympic dream doesn't pan out the way you planned.Eli grew up in triathlon literally from birth. His mom was a triathlete and swim coach, and he was racing by age seven. What started as something social and skill-based eventually evolved into elite draft-legal Olympic-distance racing on the international circuit. He came within reach of the Tokyo Olympics before a broken foot derailed his qualification, and when he looked ahead at another four-year grind toward Paris, with all the travel and time away from family it would require, he decided it wasn't worth it.What came next surprised even him. A race in Buena Vista, Colorado cracked open a new world, and trail running took hold fast. He found a coach in David Roche, started stacking results, and eventually ended up toeing the line against Roche himself at the Broken Arrow Skyrace, a moment that captures just how quickly his trajectory shifted.Ryan and Eli also get into his relationship with his wife Tabor, their shared Adidas sponsorship, and a Joshua Tree traverse FKT attempt the two are chasing together. They dig into what makes Joshua Tree such a singular and strange place to run, and why the project matters to both of them personally.On the racing front, Eli's 2026 calendar includes Black Canyon 100K and a return to Desert Rats 100K, where Ryan first spotted him, to earn his way into UTMB week races. UTMB itself is the long-term goal, even though he's only raced up to 100K so far. His best trail performance to date? OCC during UTMB week in Chamonix, and he lights up talking about the atmosphere there.The conversation also gets honest about the harder parts of moving up in distance, overheating issues, a fried hypothalamus affecting heat regulation, fueling and hydration mistakes, and how his training philosophy is evolving around high volume without necessarily high mileage, muscular endurance work, and staying adaptable.

Join us in this episode as we explore the transformative role of technology, especially AI, in aging well. Our guest, Jon Warner, a seasoned expert in healthcare and innovation for older adults, shares his journey, latest trends, and a hopeful vision for the future of personalized, preventative care that empowers individuals to thrive at any age.About JonJon Warner is an aging expert and sought-after advisor for digital health, health, healthcare and wellness organizations. Five-time company CEO, Jon is a widely respected entrepreneur having founded and led 3 startups (with 2 successful exits).His career started in the corporate world with Air Products and Chemicals, working in the US and across Europe before joining Exxon-Mobil. Following his 15 years in the corporate world, Warner founded and grew The Worldwide Centerfor Organizational Development, a management consulting business with global clients including Ford Motor Company, L'Oreal, British Airways, HSBC, Microsoft, Glaxo, Foster Wheeler, Toyota, Johnson and Johnson, Coca-Cola, PWC, The UK NHS, Roche and MasterCard.Key TakeawaysIn the past two decades, macro demographic changes have led to increased innovation and more focus on aging populations.Aging is plastic, not predetermined: Aging is a flexible process, influenced by lifestyle and epigenetic factors.Innovation in AI allows us to customize solutions and tailor them in ways that will help us to thrive and to prevail for longer in better health. AI is capable of pulling together data and creating new threads of insights.AI brings the opportunity to case-assess more richly and not only understand the care that's being rendered, but in what context the person lives. Using AI in affordable housing allows analysis of social determinants of health data—answering questions like: Does beingsocial and having a wide friend set prevent heart disease and dementiaAI needs contextual thinking provided by humans The risk of AI is misinformation from scaping the internet, which is not always reliable. We need “guidelines and guide rails.” To reduce risk, be specific with prompts and rely on credible reports and studies.Precision medicine eliminates a one-size-fits-all approach. Genomic data and social determinant data allows us to render solutions that are individualized in ways we couldn't imagine a decade ago.

The Chinese Ambassador to Ireland has confirmed he'll be exploring investment opportunities at the Roche site in Clarecastle. Zhao Xiyaun (Jow Shee-wen) visited Clare for the first time yesterday where he took in the former pharmaceutical plant, Clarecastle GAA Club, Áras Chontae An Chláir and the Cliffs of Moher on his trip. Clare FM's Daragh Dolan was in attendance for the visit at Clarecastle GAA Club where he spoke to Shannon resident and member of the Chinese Association of Ireland Sang Man and Mayor of Clare Paul Murphy, but first asked his excellency Ambassador Zhao about the purpose of his visit.

This week, we revisit our interview with Stacey Porter. Stacey is the Chief People Officer at PROCEPT BioRobotics. Prior to that, she was the Chief People Officer at Outset Medical. Stacey has expertise in organizational design, innovative talent practices, and employee engagement.  Prior to Outset, she was the Head of Global Talent Development for Intuitive Surgical, Inc., responsible for designing performance and succession practices, while developing leaders and high-performing teams. Stacey has held leadership roles at VMware and Roche, and has built a career on creating nimble, progressive organizations. She has a MSW and doctoral studies in industrial/organizational psychology.  

(00:00) Rochie comes prepared and has a game for Fred and Wallach.(18:04.659)(34:18.509) We're talking Sox and baseball with Roche.Please note: Timecodes may shift by a few minutes due to inserted ads. Because of copyright restrictions, portions—or entire segments—may not be included in the podcast.CONNECT WITH TOUCHER & HARDY: linktr.ee/ToucherandHardyFor the latest updates, visit the show page on 985thesportshub.com. Follow 98.5 The Sports Hub on Twitter, Facebook and Instagram. Watch the show every morning on YouTube, and subscribe to stay up-to-date with all the best moments from Boston's home for sports!See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of breakthroughs and strategic maneuvers that are reshaping the landscape of this dynamic industry.Roche is making waves with its antibody Gazyva, initially recognized for cancer treatment. The company has successfully ventured into autoimmune diseases, targeting kidney conditions. Recent phase 3 trials have reinforced Gazyva's efficacy in treating immune-mediated kidney diseases, building on its prior approval for lupus nephritis. This marks a potential paradigm shift from oncology to autoimmune therapy applications, offering a promising new avenue for treating complex kidney disorders. Such advancements underscore the power of immune modulation in addressing severe health conditions.Turning to oncology, Eli Lilly is expanding the use of its cancer drug, Retevmo. Originally approved for specific lung and thyroid cancers with rare biomarkers, Lilly is now exploring its use in the adjuvant setting for non-small cell lung cancer. This effort reflects a broader trend in oncology: companies are increasingly looking to extend the application of targeted therapies beyond their initial indications. This expansion could significantly enhance treatment options and improve patient outcomes.In ophthalmology, Ocular Therapeutix is preparing for an FDA filing following positive phase 3 results for its wet age-related macular degeneration treatment. Their candidate, AXPAXLI, showed superior efficacy compared to Regeneron's Eylea in head-to-head trials. Despite investor skepticism, Ocular remains confident in its product's potential to impact retinal disease management positively. The competitive landscape in ophthalmology is fierce, and innovative treatments with substantial clinical benefits over existing therapies can redefine standards of care.Eli Lilly is also strategically stockpiling Orforglipron, its oral GLP-1 candidate, in anticipation of FDA approval for obesity treatment. This proactive measure aims to prevent supply chain issues seen during previous GLP-1 launches. It reflects an industry-wide focus on ensuring product availability at launch to meet growing market demand effectively.On the regulatory front, there are significant shifts as well. The Trump administration's renewed pilot of 340B rebates aims to optimize drug pricing frameworks. Novartis has secured a long-term supply agreement with Niowave for Actinium-225 (Ac-225), crucial for developing targeted cancer therapies. This highlights the sustained demand for radiopharmaceutical isotopes as part of precision medicine initiatives.Biopharma funding is expected to recover steadily by 2026, albeit with a cautious approach favoring de-risked assets over broader platform technologies. Venture capitalists prefer predictable returns amidst an evolving market landscape.Now, let's turn to Japan, where Innovacell is planning a $92 million IPO on the Tokyo Stock Exchange. This move signals a renewed interest in biotech within the region after a long drought in IPOs. Financial strategies like these are vital for advancing cell therapies that hold promise for treating conditions once deemed challenging.Gilead Sciences has acquired synthetic lethal therapy from Genhouse Bio through a $1.5 billion deal, further underscoring the growing interest in synthetic lethality as a novel cancer treatment approach. This strategy focuses on targeting tumors while sparing normal cells, offering more effective therapies with fewer side effects.In mental health innovations, Compass Pathways has reported positive results from its pivotal trial using psilocybin for treatment-resistant depression. The success of this phase 3 trial highlights the potential role of psychedelics in psychiatric care and could revolutionize mental health treatments by providing new options Support the show

0:00 SEGMENT 1: Angelique Roche joins me to discuss her new graphic novel "The First Freedom: The Story of Opal Lee and Junteenth"22:00 SEGMENT 2: Jim Ousley comes on the show to share information about his participation in "Tales For A Halloween Night: Volume 11" from John Carpenter and Storm King Productions!!48:37 SEGMENT 3: Jim and I give our thoughts on the Oscar nominated films and who we think the winners will be!Keep up to date with 2 Rivers Comic Con, coming back to St. Charles in April 2026 ⁠https://2riverscomiccon.com/stay-in-touch/⁠ Check out the ‘Justice League Revisited Podcast' with Susan Eisenberg and James Enstall at ⁠https://anchor.fm/justiceleague⁠ Thanks to our sponsors Historic St. Charles, Missouri (⁠https://www.discoverstcharles.com/⁠), Bug's Comics and Games (⁠https://www.facebook.com/profile.php?id=100070575531223⁠)Buy Me a Coffee - ⁠https://www.buymeacoffee.com/3Y0D2iaZl⁠ Patreon -   ⁠https://www.patreon.com/GeekToMeRadio⁠ Website -   ⁠http://geektomeradio.com/⁠   Podcast -   ⁠https://anchor.fm/jamesenstall⁠ Facebook -   ⁠https://www.facebook.com/GeekToMeRadio/⁠  Twitter -   ⁠https://twitter.com/geektomeradio⁠  Instagram -   ⁠https://www.instagram.com/geektomeradio/⁠ Producer - Joseph Vosevich ⁠https://twitter.com/Joey_Vee⁠ 

As much as I think I know about the people in our community, I am still often surprised to learn about DJ's that I should already know about. This weeks guest is one of these people. In fact it feels like I'm the only one that didn't know about this guy. He's damn good too. I see what all the fuss is about. Sorry I'm late guys. He's got a residency with 3D Productions in DC, He's on the Permagrin roster, and he's a lot of other DJ's favorite DJ. Representing central PA, please welcome Bennit. Links and tracklist below. Please enjoy ❤️ Back next week -Thomas linktr.ee/bennitofficial?utm_s…ca-bd54-197ca2631100 Tracklist - 1. Wez Walker - Is This Love 2. Dramatic - One Dream 3. Kinsella, bd:j - Ruthless 4. Kublai - Young Soul (Note Remix) 5. London Elektricity - Lozenge Frenzy 6. Oli Lewis - Proportional 7. Minor Forms, Zero T - Shifty 8. R3IDY - Temperament 9. Revan, Primitive Instinct - The Vault 10. Roche, Klimate - Devise 11. Rockwell - Only 12. T>I, Zombie Cats - Search & Destroy (Magneta Remix) 13. TOAL - Fresh 14. Vital - Outlined 15. Yannons - Vanquished 16. Warm Roller - Trouble 17. Rufige Kru - Still The Same (Ft. CASISDEAD)(Submotive Remix) 18. Para - Null 19. Oli Lewis - Advocate 20. Nepo & Whisper - Heppier You 21. L-Side, MC GQ - Deep In The Trenches 22. Kasra - hydrogen 23. Kublai - Feel Me 24. GrayMata - Eliminate 25. Molecular - One Dub 26. Minor Forms - Warp Speed 27. Melysma - Disguise 28. Manikin - Waste No Time 29. DRS, Zar, Verbz - I Wonder 30. Dubtype - Go Straight VIP 31. Covert Garden - Work It Out 32. K Sonic - Do You Wrong 33. Nasz - Goodbye 34. Braidee - Dreamstate

Come listen to a WUU service! Science is one of humanity's greatest achievements: a disciplined way of turning curiosity into reliable knowledge about who we are, where we came from, and how life became capable of thought, feeling, and compassion. Today we celebrate the scientists—past and present—whose patient work reveals the deep story written in our bodies and minds, enlarging our sense of what it means to be human. Thank you for listening. For more information about the Williamsburg Unitarian Universalists, or to join us on Sunday mornings, visit www.wuu.org. Permission to reprint, podcast, and/or stream the music in this service obtained from ONE LICENSE with license #A-735438. All rights reserved.

Employment Report Solid The Tech disruptors are getting disrupted… Growth vs Value – an abrupt change. Guest – Cullen Roche – Author of the bestselling book – Your Perfect Portfolio.   NEW! DOWNLOAD THE AI GENERATED SHOW NOTES Cullen Roche founded Discipline Funds to help investors obtain access to low fee, diversified portfolios that help them stay the course and meet their financial goals. Cullen's primary areas of expertise include global macro portfolio construction, quantitative risk management, monetary economics, financial accounting and behavioral finance. Prior to establishing his own business, Cullen worked at Merrill Lynch Global Wealth Management where he worked on a team overseeing $500MM+ in assets under management. Upon leaving Merrill Lynch, Cullen managed a private investment partnership which took advantage of reporting irregularities ahead of major corporate events. The strategy generated substantial positive alpha (high risk adjusted returns) without a single negative year of returns from 2005-2011. He formed Orcam Financial Group in 2012 to help better serve the much needed retail space with sophisticated but low fee asset management and financial planning services. Cullen is also a prolific writer. In addition to the weekly musings on his website Pragmatic Capitalism, he is the author of the popular book Pragmatic Capitalism: What Every Investor Needs to Know About Money and Finance as well as “Understanding the Modern Monetary System,” one of the top 10 all-time most downloaded research papers on the SSRN academic research network. He is also the author of the popular white paper “Understanding Modern Portfolio Construction.” He was named one of the “Top Wall Street Economists, Experts and Opinion Leaders” of 2011 by Wall Street Economists and was named one of the “101 Best Finance People” by Business Insider, where he was described as “one of the most influential economic thinkers today.” In 2015, Cullen was named one of the “40 Under 40” most influential people in finance by InvestmentNews. He is regularly cited in the Wall Street Journal, on CNBC and in the Financial Times. His latest book is YOUR PERFECT PORTFOLIO: The Ultimate Guide to Using the World’s Most Powerful Investing Strategies . In that, Roche draws on two decades of experience building investment firms and advising clients to help readers discover the strategy that fits their goals Check this out and find out more at: http://www.interactivebrokers.com/ Follow @andrewhorowitz Looking for style diversification? More information on the TDI Managed Growth Strategy – HERE Stocks mentioned in this episode: (INTC), (UEC), (IONQ), (CEG), (OKLO), (NXT)

Synopsis: At the heart of JPM 2026's biotech buzz, Alok Tayi sits down with Fred Aslan, CEO of Artiva, to explore how bold platform bets, scalable cell therapies, and autoimmune breakthroughs could reshape medicine. Fred traces his journey from medical school in Brazil to consulting at BCG, venture capital, and ultimately founding multiple companies—sharing why following curiosity, not rigid career ladders, shaped his path. Fred dives deep into the bottlenecks holding back traditional CAR-T therapies—manufacturing complexity, cost, hospitalization, and toxicity—and explains how Artiva's off-the-shelf NK-cell platform aims to change the paradigm. The discussion explores why rheumatoid arthritis became Artiva's lead indication, how immune “resets” could redefine autoimmune care, and what's ahead in 2026 as the company prepares registrational trials and expands its basket studies across lupus, myositis, scleroderma, and more. The episode closes with rapid-fire takes on AI in drug development, China's accelerating biotech engine, rare disease trial models, and the strategic principles founders should follow when choosing indications and building durable platforms. Biography: Fred Aslan, M.D., has a 20-year track record as an executive and investor in the life sciences industry. He was most recently President and CBO at Vividion Therapeutics, where he was responsible for business development, finance, alliance and project management, and operations. Dr. Aslan had the opportunity to lead Vividion's Series B financing and $135M-upfront collaboration with Roche. Prior to Vividion, Dr. Aslan had a 12-year affiliation with Venrock. Initially he was an investor from 2006 to 2013, when he cofounded and served as a board member of Receptos Pharmaceuticals (acquired by Celgene for more than $7 billion). Dr. Aslan led Venrock's investment in Zeltiq (acquired by Allergan for more than $2 billion) and was involved in the early formation of Fate Therapeutics. Subsequently as an entrepreneur from 2013 to 2018, he was CEO of Adavium Medical, a Brazilian medical device company, which he grew from zero to 350 employees, sales of over US$40 million, and fully integrated R&D, manufacturing, and commercial capabilities. Prior to Venrock, Dr. Aslan was Director of Business Development and Head of Investor Relations for CuraGen, a Nasdaq-listed oncology-focused biotech company. Prior to CuraGen, he was a consultant at Boston Consulting Group (BCG). Dr. Aslan holds a B.S. in biology from Duke University, an M.D. from Yale School of Medicine, and an MBA from Harvard Business School.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a range of stories that highlight the dynamic and often challenging landscape of these industries, as they navigate through scientific breakthroughs, strategic collaborations, regulatory hurdles, and market trends.Starting with corporate restructuring, Roche's Genentech has announced significant layoffs, totaling 489 positions in the previous year. This move is part of broader restructuring efforts seen across large pharmaceutical companies like Bayer and Bristol Myers Squibb. The layoffs illustrate the tightening financial and scientific constraints that are influencing pipeline decisions and capital allocation. Companies are facing increasing pressures to maintain credibility while also dealing with economic challenges that impact their strategic directions.On the regulatory front, the U.S. Department of Health and Human Services (HHS) encountered legal setbacks concerning its 340B rebate model pilot program. Following a lawsuit from the American Hospital Association, HHS withdrew notices and application approvals for this initiative. This development indicates a need for more comprehensive public feedback before any future attempts at similar programs are made, highlighting how complex regulatory landscapes can become.Turning to clinical trials, Fierce Biotech identified several significant failures in 2025, underscoring the inherent risks involved in drug development. These setbacks emphasize the importance of robust trial designs and execution strategies to mitigate risks. Meanwhile, Fresenius Kabi and Phlow Corporation have announced a strategic alliance to produce epinephrine injection API in the U.S., aiming to strengthen supply chain resilience—a crucial lesson learned from vulnerabilities exposed during the COVID-19 pandemic.Eli Lilly has made waves with its $2.4 billion acquisition of Orna Therapeutics, marking its entry into the in vivo CAR-T space. This acquisition underscores a growing interest in advanced cell therapies with transformative potential for cancer treatment. Additionally, Lilly has expanded its collaboration with Innovent Biologics through a $350 million upfront payment and milestone payments totaling $8.8 billion, focusing on oncology and immunology. This reflects a shift towards deeper integration in drug development efforts beyond traditional licensing models.Takeda Pharmaceuticals' $1.7 billion AI-driven drug discovery agreement with Iambic Therapeutics highlights the increasing adoption of artificial intelligence to accelerate drug discovery processes. AI's potential to enhance precision medicine approaches is becoming more pronounced as companies seek innovative methods to improve target identification and lead optimization.In market dynamics, Hims & Hers withdrew from launching a generic version of Novo Nordisk's weight loss pill due to regulatory pressures from the FDA. This incident underscores the complex interplay between innovation and compliance that companies must navigate when bringing new therapeutics to market. Additionally, legal actions have been initiated by Novo Nordisk against Hims & Hers over patent infringement claims related to semaglutide—a case highlighting ongoing challenges in patent protection within rapidly evolving drug compounding arenas.Eli Lilly also leveraged the global stage of the Winter Olympics for a campaign drawing parallels between scientific progress and athletic achievement. Such campaigns align with industry efforts to enhance public perception and trust amid ongoing challenges.Overall, while the pharmaceutical and biotech industries face significant challenges—from regulatory hurdles to clinical trial setbacks—there are substantial opportunities for growth driven by technological advancements and strategic collaborations. NaSupport the show

In Episode 462 of Hidden Forces, Demetri Kofinas speaks with Cullen Roche, the Founder and CIO of Discipline Funds and author of the new book "Your Perfect Portfolio." They discuss the essential principles of portfolio construction by dissecting some of the world's most influential investment strategies―from Warren Buffett's classic approach to the momentum-driven tactics of trend followers, and even innovative frameworks you've likely never seen before.  Cullen and Demetri spend the first hour discussing Roche's philosophy on portfolio construction, what goes into constructing the perfect portfolio, and how variables like one's time horizon, financial circumstances, and behavioral biases are arguably the most important determinants of financial returns, and therefore, must be actively taken into account when structuring your portfolio. They explore the distinction between saving and investing, the hidden costs that erode portfolio performance, and why managing the liability side of your balance sheet is arguably more important than any other decision in portfolio construction.  The second hour is a deep dive into specific portfolio strategies, including the permanent portfolio, the endowment portfolio, the Buffett portfolio, dividend investing, counter-cyclical rebalancing, and Cullen's favorite: the defined duration portfolio. Roche explains how to think about asset allocation across different time horizons, the role of gold and other insurance-like assets in one's portfolio, the importance of cost control in financial life, and practical frameworks for managing behavioral responses to market volatility. Subscribe to our premium content—including our premium feed, episode transcripts, and Intelligence Reports—by visiting HiddenForces.io/subscribe. If you'd like to join the conversation and become a member of the Hidden Forces Genius community—with benefits like Q&A calls with guests, exclusive research and analysis, in-person events, and dinners—you can also sign up on our subscriber page at HiddenForces.io/subscribe. If you enjoyed today's episode of Hidden Forces, please support the show by: Subscribing on Apple Podcasts, YouTube, Spotify, Stitcher, SoundCloud, CastBox, or via our RSS Feed Writing us a review on Apple Podcasts & Spotify Join our mailing list at https://hiddenforces.io/newsletter/ Producer & Host: Demetri Kofinas Editor & Engineer: Stylianos Nicolaou Subscribe and support the podcast at https://hiddenforces.io. Join the conversation on Facebook, Instagram, and Twitter at @hiddenforcespod Follow Demetri on Twitter at @Kofinas Episode Recorded on 02/02/2026

Who will make decisions for you when you can't? For Childfree people, that question has never had a good answer until now.In this episode, Maddy Roche and Dr. Jay Zigmont, CFP® introduce Childfree Trust®, the first nationwide professional fiduciary solution designed specifically for Childfree individuals. After three and a half years of research and development, Childfree Trust® solves a problem that's plagued the Childfree community: who will act as your medical power of attorney, financial power of attorney, executor, and trustee when you don't have the traditional next of kin most estate planning assumes you have?Jay and Maddy break down the four crucial estate planning roles every person needs to fill, what really happens if you don't have these documents in place, and why relying solely on friends and family can put everyone in a difficult position. Key Takeaways:Estate planning is about decisions while you're alive: The four critical roles,  medical power of attorney, financial power of attorney, executor, and trustee, ensure someone can make decisions on your behalf during emergencies, cognitive decline, or after death. Childfree Trust® is the first nationwide professional fiduciary solution: Acting in all 50 states & DC, Childfree Trust® can serve as your medical power of attorney, financial power of attorney, executor, or trustee. Professional fiduciaries protect everyone involved: Even if you have someone willing to serve in estate planning roles, appointing Childfree Trust® as a backup gives your loved ones an out if circumstances become too challenging. Guarantees ensure lifelong protection: If you've been a client for 24 consecutive months and go on Medicaid, Childfree Trust® will continue making decisions on your behalf without billing you. Your decisions are protected even if you run out of assets.Episode Hosts:Maddy Roche - Chief Growth Officer at Childfree Trust® and responsible for all sales & marketing initiatives.Dr. Jay Zigmont, CFP® - Founder & CEO of Childfree Wealth®, Childfree Trust®, & Childfree Insights. After spending three and a half years researching estate planning solutions for Childfree people, Jay created Childfree Trust® to solve a problem no one else would address.

What if you never had to apply for a job again? Greg Roche hasn't submitted a resume since 2013—and it's not because he's lucky. It's because he discovered a better way to build real, lasting professional connections without networking events, name tags, or forced small talk. In this interview, you'll learn: Why networking is broken—and how to fix it The power of reconnecting with people you already know The exact approach Greg used to land jobs without applying How to network as an introvert (without feeling awkward or salesy) Why you don't need a pitch—just a simple, authentic message Connect with Greg Greg's YouTube Channel www.gregsroche.com

If you're considering gamification for engagement, retention, or loyalty, I'm happy to compare options with you: professorgame.com/chat The biggest impact of gamification often happens in the least obvious places. In this episode, Rob Alvarez talks with David Dand about using game-inspired strategies in recruitment, leadership, and employee experience to attract better-fit talent, reduce churn, and build stronger, more human organizations, even in highly traditional sectors. David is the Founder and Managing Director of Coreus, a boutique hiring services provider based in Brighton. Coreus specialises in helping professional SMEs tackle critical talent challenges and is experienced in the complexities of recruiting in skilled, competitive, and often highly regulated markets. David is a CIPD-qualified HR and recruitment expert with a career spanning global firms such as EY, AXA, and Roche, with a focus on cultural fit, leadership assessment, and career coaching. He lives in the South Downs near Brighton, UK, with his wife and their three mischievous children. His interests include music, travel, and sport. Rob Alvarez is Head of Engagement Strategy, Europe at The Octalysis Group (TOG), a leading gamification and behavioral design consultancy. A globally recognized gamification strategist and TEDx speaker, he founded and hosts Professor Game, the #1 gamification podcast, and has interviewed hundreds of global experts. He designs evidence-based engagement systems that drive motivation, loyalty, and results, and teaches LEGO® SERIOUS PLAY® and gamification at top institutions including IE Business School, EFMD, and EBS University across Europe, the Americas, and Asia.   Guest Links and Info Website: Gamification in Recruitment | Coreus LinkedIn: Personal: David Dand | LinkedIn Company: Coreus Instagram: @coreus_talentacquisition   Links to episode mentions: Recommended book: Hiring Success by Jerome Ternynck Favorite game: Chess and Football   Lets's do stuff together! Let's chat about your gamification project Start Your Community on Skool for Free YouTube LinkedIn Instagram Facebook Ask a question

#685: You're not an investor. You're a saver. That's the first of 10 principles Cullen Roche shares in this conversation about building what he calls "the perfect portfolio." Roche, the founder and chief investment officer of Discipline Funds, argues that when you buy stocks on the secondary market, you're not actually funding companies or making investments in the traditional economic sense. You're just swapping your cash for someone else's stock position – reallocating your savings. This reframe matters because it changes your entire approach. Instead of trying to beat the market, you focus on the boring, prudent work of allocating your savings across different time horizons. We walk through all ten of Roche's principles. He explains why you are your portfolio's worst enemy – not just because fear makes you panic-sell during crashes, but because FOMO during bull markets leads you to chase performance at exactly the wrong time. He breaks down why diversification is the only free lunch in investing, why costs matter more than you think, and why real returns are the only ones that count after you strip out inflation, taxes, and fees. Roche introduces some concrete strategies most people have never heard of. The 351 exchange lets you swap concentrated stock positions into diversified ETFs without triggering immediate capital gains taxes. The "defined duration" approach matches specific pools of money to specific future expenses—like pairing a six-month treasury bill with next year's bathroom remodel. He also tackles the hardest allocation question: what to do with money earmarked for three to ten years from now. That awkward middle timeframe sits between "keep it in cash" and "put it in stocks," and Roche explains why traditional approaches like sixty-forty portfolios don't always work. The conversation covers everything from why long-term bonds make terrible matches for long-term goals to why thinking in time horizons beats thinking in investment styles. Timestamps: Note: Timestamps will vary on individual listening devices based on dynamic advertising run times. The provided timestamps are approximate and may be several minutes off due to changing ad lengths.

(00:00) Principle 1: you're a saver, not an investor (04:48) Real wealth comes from direct business ownership (06:43) Principle 2: you are your portfolio's worst enemy (09:58) FOMO during bull markets vs fear during crashes (12:43) Principle 3: beating the market is hard (15:18) The 5 percent "fun money" allocation debate (16:18) What to do when your position explodes (17:18) The 351 exchange tax strategy explained (20:28) Should you rebalance concentrated stock positions (22:18) Principle 4: diversification is the only free lunch (31:03) Gold and stock market both high simultaneously (35:43) When diversification becomes diworsification (40:03) Principle 5: the cost matters hypothesis (44:23) HSAs, 401ks and unavoidable fee structures (47:03) Why ETFs beat mutual funds on taxes (51:03) Principle 6: real, real returns matter most (1:00:58) Principle 7: risk is uncertainty of lifetime consumption (1:06:18) Longevity risk and unpredictable healthcare costs (1:13:03) Principle 8: asset allocation as temporal conundrum (1:24:43) The 3-10 year allocation problem explained (1:28:03) Principle 9: past performance doesn't predict future (1:31:18) Principle 10: set realistic expectations, stay the course Resources: Cullin's website and newsletter: https://disciplinefunds.com Grab the FREE handbook: https://affordanything.com/financialgoals Learn more about your ad choices. Visit podcastchoices.com/adchoices

Friend, put your phone down. Quit doomscrolling. You owe it to yourself and everyone else who came before you. It's time to get in the fight, and First Freedom: The Story of Opal Lee and Juneteenth by Angélique Roché, Alvin Epps, Millicent Monroe, and Bex Glendining is a comic designed to inject some serious motivation into your social media-addled, catatonic body. The fight may be new to you, but it's been raging for centuries. That's not a despairing thought; it's an activating one, and once you stand on the shoulders of the heroes that came before, you'll find the perspective required to block the hateful from gaining any more ground than they already have. As a comic book reader, you already have all the tools and knowledge to resist fascism. On this week's podcast, we chat with journalist, comic creator, and podcaster Angélique Roché. Once approached to write First Freedom: The Story of Opal Lee and Juneteenth, she threw herself into an intense research phase. We discuss the stress and excitement of the process, and the motivation she secured in telling Dr. Opal Lee's life story. Juneteenth was only recognized as a national holiday in 2021. It's the first new federal holiday since Martin Luther King Day was signed into law in 1983. It never would have happened without Dr. Opal Lee and the lessons she learned from other warriors over her extraordinary lifetime. First Freedom: The Story of Opal Lee and Juneteenth arrives in comic book shops and bookstores, thanks to Oni Press, on February 10th. Make sure you follow Angélique Roché via her website, Bluesky, and Instagram. This Week's Sponsors The Future is Calling! 2000 AD is the Galaxy's Greatest Comic, with new issues published every single week! Every 32-page issue of 2000 AD brings you the best in sci-fi and horror, featuring characters like Judge Dredd, Rogue Trooper, and more. Get a print subscription to 2000 AD and it'll arrive to your mailbox every week - and your first issue is free! Or subscribe digitally, and you can download DRM-free copies of each issue for only $9 a month. That's 128 pages of incredible comics every month for less than $10! Head to 2000AD.com and click on ‘subscribe' now – or download the 2000 AD app and start reading today! Other Relevant Links to This Week's Episode: Subscribe to The Stacks, Comic Creators Name Their Favorite Comics The Comic Book Couples Counseling TeePublic Merch Page. Stand with Minnesota Buy Books from Greg Ketter and DreamHaven Books Daniel Warren Johnson on Absolute Batman Annual Comic Book Club: Black Arms to Hold You Up at Meanwhile...Coffee in Herndon, Virginia, on 2/1 at 3:30 PM Comic Book Film Club: Blade at the Alamo Drafthouse Winchester on 2/15 Final Round of Plugs (PHEW): Support the Podcast by Joining OUR PATREON COMMUNITY. And, of course, follow Comic Book Couples Counseling on Facebook, on Instagram, and on Bluesky @CBCCPodcast, and you can follow hosts Brad Gullickson @MouthDork & Lisa Gullickson @sidewalksiren. Send us your Words of Affirmation by leaving us a 5-star Review on Apple Podcasts. Continue your conversation with CBCC by hopping over to our website, where we have reviews, essays, and numerous interviews with comic book creators. Podcast logo by Jesse Lonergan and Hassan Otsmane-Elhaou.

This episode of The Edge of Show was recorded live at the Future of Money, Governance, and the Law (FOMGL) 2025 event in Washington, D.C. In this episode, we dive deep into the evolving landscape of finance, exploring the intersection of traditional finance (TradFi) and decentralized finance (DeFi).Join Mariana de la Roche alongside distinguished panelists including Joanna Rindell, Annelise Osborne and Charlie Hu as they discussInsights from leaders in the Tezos ecosystem, Bitcoin L2 systems, and innovative blockchain projects.The transformation of finance over the past two decades and the future of DeFi.The impact of regulatory developments like the Clarity Act and Mika on the DeFi space.Real-world applications of DeFi, including tokenization of assets and social impact projects.The importance of financial literacy in navigating the DeFi landscape.Tune in to discover how DeFi is reshaping our financial future and what it means for both individuals and institutions!Don't forget to like, subscribe, and hit the notification bell to stay updated on our latest episodes!____

In this special three-part series on the recent consistory, Father McTeigue begins an examination of the questionable claims made by Cardinal Roche about the liturgy. Father finishes with Weekend Readiness to prepare you for Sunday Mass. Show Notes ENGLISH EXCLUSIVE: Cardinal Roche Defends Traditionis Custodes at Extraordinary Consistory  Bishop Athanasius Schneider: Cardinal Roche's Liturgy Report Is “Manipulative” and Distorts History  Does 'Traditionis Custodes' Pass the Juridical Rationality Test? – Os Justi Press  The Latin Mass and the Intellectuals: Petitions to Save the Ancient Mass from 1966 to 2007 Ottaviani Intervention (1969) | Latin Mass Society  The text Card. Roche gave the other Cardinals about the TLM, ‘Traditionis custodes' and “unity” during the recent consistory: an examination of “The Roche Report” | Fr. Z's Blog  The Church Speaks to the Modern World: The Social Teachings of Leo XIII | Etienne Gilson Has the new liturgy changed you? | Charlotte was Both Franz Kafka, Nancy Drew and Charlie Parker Become Free to Use Ahead Of March For Life, Trump Admin Ends Funding For Research Using Aborted Baby Tissue Third Sunday in Ordinary Time | USCCB iCatholic Mobile The Station of the Cross Merchandise - Use Coupon Code 14STATIONS for 10% off | Catholic to the Max Read Fr. McTeigue's Written Works! "Let's Take A Closer Look" with Fr. Robert McTeigue, S.J. | Full Series Playlist Listen to Fr. McTeigue's Preaching! | Herald of the Gospel Sermons Podcast on Spotify Visit Fr. McTeigue's Website | Herald of the Gospel Questions? Comments? Feedback? Ask Father!